Biotaitan Molmed CO., LTD.
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
Our core product, the AcesoBox, is a point-of-care molecular testing platform that delivers multi-target, rapid, highly sensitive, and precise diagnostics, enabling testing anytime and anywhere. This next-generation ultra-fast molecular diagnostic system completes nucleic acid tests within 10–15 minutes by integrating a patented rapid thermal cycling system with multi-channel optical detection. Users simply insert minimally processed samples into reagent tubes to obtain results for 15 nucleic acid targets, covering infectious diseases, high-sensitivity myocardial infarction screening, sexually transmitted infections, sepsis, and cancer. Combining rapid PCR and immuno-PCR technologies, the system provides multi-omics insights—including genomics, transcriptomics, proteomics, and metabolomics—enhanced with AI analysis for precision medicine. Suitable for hospitals, clinics, diagnostic labs, ambulances, field use, and home environments, Titan also offers complete solutions encompassing reagent development, microfluidic cartridge design, and micro-optical detection system integration.
The content above was translated by Ai
Founded Year
2023
Unified Business No.
83004262
Status
Active
Number of Employees
6
Total Paid-in
Capital
18,349,328 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Biotaitan Molmed, founded in 2023, develops precision medical and rapid molecular diagnostic platforms. Their technology covers multi-target molecular diagnostics, rapid thermal cycling modules, and micro-optical reading systems. Collaborating with academic institutions and hospitals, Biotaitan Molmed aims to provide high-quality, innovative diagnostic tools for smarter, faster healthcare decisions globally.
The content above was translated by Ai
